Research programme: organ protection therapeutics - KBP Biosciences

Drug Profile

Research programme: organ protection therapeutics - KBP Biosciences

Alternative Names: Anti cancer therapeutics - KBP Biosciences; Anti fibrotics - KBP Biosciences; KBP-7018

Latest Information Update: 09 Sep 2014

Price : $50

At a glance

  • Originator KBP Biosciences
  • Class
  • Mechanism of Action Protein tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Idiopathic pulmonary fibrosis
  • Research Cancer

Most Recent Events

  • 03 Sep 2014 Preclinical trials in Idiopathic pulmonary fibrosis in China (PO)
  • 03 Sep 2014 Early research in Cancer in China (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top